The Company is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products.
The main business focuses on immune cell therapy that uses genetic engineering to modify the patient s own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
History
The Company was established on March 30, 2017.The Company listed on Public Companies of Taiwan Stock Exchange on March 8, 2024.The Company listed on TSEC of Taiwan Stock Exchange on March 8, 2024.
总部
4F.,No.87,Xinhu 2Nd Rd, Neihu Dist
台北市; 台北市;
联系方式: 购买Pell Bio-Med Technology Co. Ltd.报告以查看信息。
EMIS公司简介是一个更大的信息服务的一部分，它结合了公司，行业和国家数据和分析在超过125个新兴市场.
请求EMIS服务的演示查看更多信息, 申请试用